Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: Mkt Overreacts to Potential Biopharma Tech Export Restrictions, Creating Buy Opportunities
Recommend 15 Positive 23 Negative 15 |
||||
|
||||
|
On June 4 (yesterday), Citi invited a senior pharmaceutical innovation policy expert to host an expert conference call. According to the expert, authorities recognize that the core competitive advantage of the industry lies in efficient clinical validation rather than in the invention of technology itself. Therefore, regulators will continue to encourage compliant out-licensing of innovative drugs. Stricter regulatory measures would only target extreme cases involving the export of critical core technologies. The expert also noted that companies with offshore IP structures, offshore clinical trial data, and a single-asset out-licensing model will be best positioned. Citi’s top picks in the pharmaceuticals/biotechnology sector are HENGRUI PHARMA (01276.HK), CSPC PHARMA (01093.HK), ASCLETIS-B (01672.HK) and INNOVENT BIO (01801.HK). The broker believed the market has overreacted to potential policies restricting biopharmaceutical technology exports, creating good buying opportunities for investors. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
